OXYCONTIN 80mg. Tablets.

$750.00$3,000.00

in stock
SKU: OXYCONTIN-80

Product it’s in Stock and ready to go out, the Price include the release of the Prescription, Duty Free, Tax and all Fees, and We also send all orders from a Safe Place, to avoid Mail Lifters, Customs Hassle and Shipping Issues, and We always use Special Courier Companies like FedEx and/or U.P.S. Via Two Days Air and/or Second Day Air, with no signature required, and We do send discrete flat envelope with no Medical or Pharmaceutical Tags, to Protect the Right of Privacy of our Customers; We also have a Confidentiality Clause, and We don’t Share Information with Third Persons.

Clear

Description

This Product belong to the Opioid Narcotic Pain Medication Group, Classified by the F.D.A. On Schedule # II of Controlled Substances, for Exclusive use of Clinics & Hospitals; This is why is hard for other Sources to get this from the Original Laboratory approved by the F.D.A. Like the ones We Offer, and also in a Lower Price, because of all the Expenses they represent

And also, this is why all other Non Reliable and Suspicious Sources that Offer this Product, they are: Street Unknown Drug, Fake Product, Weak Generic, HomeMade or Counterfeit, from other unknown Countries with no Health Regulations, like Pakistan, India, China, Asian, or Central and South America, and also, we are the top # 1 most Reliable and Best Rated Source, from over 300 places, there were They Recommended You with Us.

 

Ps. Buying products from the street, you have the risk to get poisoned or strong infection by not regulated fake drug mix they offer, made in Clandestine laboratory in the worst health conditions

 

FORMULATION:

Oxycodone  Hydrochloride 80mg.

 

BOXED WARNING

DOSAGE & INDICATIONS

 

For the treatment of severe pain.
For the treatment of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Oral dosage (immediate-release capsules, tablets, and oral solution)
Adults

5 to 15 mg PO every 4 to 6 hours as needed for pain for opioid-naive patients. For control of chronic, severe pain, consider dosing on a regularly scheduled basis every 4 to 6 hours. For conversion from other opioid therapy, factor the potency of the prior opioid relative to oxycodone into the selection of the total daily dose of oxycodone. Use the same dose and dosing regimen to convert between RoxyBond immediate-release tablets and other oxycodone immediate-release formulations. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions.

Children† and Adolescents† 5 years or older

0.2 mg/kg PO given 30 minutes preprocedure reduced pain associated with wound care in children aged 5 to 14 years (16.6 to 56 kg); the oxycodone regimen was compared to an oral transmucosal fentanyl regimen. As rated by the children, pain scores were not significantly different between the 2 treatment groups before drug receipt, immediately before wound care, or at the end of wound care. Both drugs were well tolerated. 0.2 mg/kg PO then 0.1 to 0.3 mg/kg PO every 3 to 4 hours has been used successfully for acute bone fracture pain management. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions.

For the management of chronic severe pain in patients who require daily, around-the-clock, long-term opioid treatment.
NOTE: Extended-release oxycodone should be reserved for patients in whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would otherwise provide inadequate pain management. Discontinue all other around-the-clock opioid drugs upon initiation of oxycodone extended-release tablets or capsules.
NOTE: Extended-release oxycodone 60 or 80 mg tablets, a single tablet dose more than 40 mg, or a total tablet daily dose more than 80 mg should be reserved for opioid-tolerant patients. A single extended-release oxycodone capsule dose of 36 mg (equivalent to 40 mg oxycodone hydrochloride) or more or a total capsule daily dose of 72 mg (equivalent to 80 mg oxycodone hydrochloride) or more should be reserved for opioid-tolerant patients. Adult patients who are opioid tolerant are those receiving, for a minimum of 1 week, 60 mg or more oral morphine daily, 30 mg or more oral oxycodone daily, 8 mg or more oral hydromorphone daily, 25 mg or more oral oxymorphone daily, 25 mcg or more transdermal fentanyl per hour, 60 mg or more oral hydrocodone per day, or an equivalent dose of another opioid. Extended-release oxycodone tablets should only be used in pediatric patients 11 years or older receiving opioids for at least 5 consecutive days and taking a minimum of 20 mg per day of oxycodone or its equivalent for 2 days immediately preceding dosing with extended-release oxycodone.
Oral dosage (extended-release tablet, Oxycontin or generic equivalents) for use as the first opioid analgesic or in patients who are not opioid-tolerant
Adults

10 mg PO every 12 hours. Reduce the starting dose to one-third to one-half the usual dosage in debilitated, nonopioid-tolerant patients. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days.

Oral dosage (extended-release tablet, Oxycontin or generic equivalents) for conversion from other oral oxycodone formulations
Adults

Convert to an equivalent total daily oxycodone dose and divide the 24-hour oxycodone requirements into 2 equal doses given PO every 12 hours. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days.

Children and Adolescents 11 years or older

Use only in patients receiving opioids for 5 or more consecutive days and taking 20 mg/day or more of oxycodone or its equivalent for 2 days immediately preceding dosing. Convert to an equivalent total daily oxycodone dose and divide the 24-hour oxycodone requirements into 2 equal doses given PO every 12 hours. If rounding is necessary, always round the dose down to the nearest available tablet strength. If the calculated dose is less than 20 mg/dose, there is no safe strength for conversion; do not initiate extended-release oxycodone. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% every 1 to 2 days as needed.

Oral dosage (extended-release tablet, Oxycontin or generic equivalents) for conversion from fentanyl transdermal patch
Adults

10 mg PO every 12 hours for each 25 mcg/hour fentanyl transdermal patch beginning 18 hours after removal of the fentanyl transdermal patch. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days.

Children and Adolescents 11 years or older

Limited data in pediatric patients. Use only in patients receiving opioids for 5 or more consecutive days and taking 20 mg/day or more of oxycodone equivalent for 2 days immediately preceding dosing. 10 mg PO every 12 hours for each 25 mcg/hour fentanyl transdermal patch beginning at least 18 hours after removal of the fentanyl transdermal patch. If rounding is necessary, always round the dose down to the nearest available tablet strength. If the calculated dose is less than 20 mg/dose, there is no safe strength for conversion; do not initiate extended-release oxycodone. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% every 1 to 2 days.

Oral dosage (extended-release tablet, Oxycontin or generic equivalents) for conversion from other opioid agonist analgesics
Adults

10 mg PO every 12 hours. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days. Use extreme caution when converting patients from methadone as the ratio between methadone and other opioid agonists can vary widely.

Children and Adolescents 11 years or older

Use only in patients receiving opioids for 5 or more consecutive days and taking 20 mg/day or more of oxycodone or its equivalent for 2 days immediately preceding dosing. To convert to extended-release oxycodone, calculate the 24-hour opioid requirement and multiply this amount by the conversion factor provided in the FDA-approved labeling. The conversion factors are as follows: 0.9 for oral hydrocodone, 4 for oral hydromorphone, 20 for parenteral hydromorphone, 0.5 for oral morphine, 3 for parenteral morphine, 0.17 for oral tramadol, and 0.2 for parenteral tramadol. For patients receiving high-dose parenteral opioids, a more conservative conversion is warranted; for example, use a conversion factor of 1.5 instead of 3 for patients receiving high-dose parenteral morphine. Divide the calculated total daily dose into 2 equal doses given PO every 12 hours. If rounding is necessary, always round the dose down to the nearest available tablet strength. If the calculated dose is less than 20 mg/dose, there is no safe strength for conversion; do not initiate extended-release oxycodone. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% every 1 to 2 days.

Oral dosage (extended-release capsule, Xtampza ER) for use as the first opioid analgesic or in patients who are not opioid-tolerant
Adults

9 mg PO every 12 hours. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days. Use an alternate analgesic for patients who require a dose less than 9 mg.

Oral dosage (extended-release capsule, Xtampza ER) for conversion from other oral oxycodone formulations
Adults

Convert to an equivalent total daily oxycodone dose and divide the 24-hour oxycodone requirements into 2 equal doses given PO every 12 hours. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days. Because extended-release capsules are not bioequivalent to other extended-release oxycodone products and the relative bioavailability of immediate-release oxycodone products to extended-release oxycodone is unknown, monitor patients for possible dosage adjustment. Use an alternate analgesic for patients who require a dose less than 9 mg.

Oral dosage (extended-release capsule, Xtampza ER) for conversion from fentanyl transdermal patch
Adults

9 mg PO every 12 hours for each 25 mcg/hour fentanyl transdermal patch beginning 18 hours after removal of the fentanyl transdermal patch. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days. Use an alternate analgesic for patients who require a dose less than 9 mg.

Oral dosage (extended-release capsule, Xtampza ER) for conversion from other opioid agonist analgesics
Adults

9 mg PO every 12 hours. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Titrate the total daily oxycodone dose by 25% to 50% every 1 to 2 days. Use extreme caution when converting patients from methadone as the ratio between methadone and other opioid agonists can vary widely. Use an alternate analgesic for patients who require a dose less than 9 mg.

For the treatment of painful diabetic neuropathy†.
Oral dosage (extended-release tablets, e.g., Oxycontin or generic equivalent)
Adults

10 mg PO every 12 hours initially. Titrate dosage every 2 to 7 days up to a maximum of 120 mg/day PO, given in divided doses. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. The American Academy of Neurology guidelines consider extended-release oxycodone as probably effective in lessening the pain of diabetic neuropathy.

†Indicates off-label use

MAXIMUM DOSAGE

Adults

Immediate-release dosage forms, extended-release tablets: There is no maximum dose of oxycodone; however, careful titration of oxycodone, especially in opiate-naive patients, is required until tolerance develops to some of the side effects (i.e., drowsiness and respiratory depression). Individualize dosage carefully.
Extended-release capsules (Xtampza ER): 288 mg/day PO (equivalent to 320 mg/day oxycodone hydrochloride).

Geriatric

Immediate-release dosage forms, extended-release tablets: There is no maximum dose of oxycodone; however, careful titration of oxycodone, especially in opiate-naive patients, is required until tolerance develops to some of the side effects (i.e., drowsiness and respiratory depression). Individualize dosage carefully.
Extended-release capsules (Xtampza ER): 288 mg/day PO (equivalent to 320 mg/day oxycodone hydrochloride).

Adolescents

Extended-release tablets: With appropriate dosage titration, there is no maximum dose of extended-release oxycodone in opioid-tolerant pediatric patients; however, careful titration is required until tolerance develops to some of the side effects (i.e., drowsiness and respiratory depression). Individualize dosage carefully.
Immediate-release dosage forms and extended-release capsules (Xtampza ER): Safety and efficacy have not been established.

Children

Extended-release tablets in Children 11 years or older: With appropriate dosage titration, there is no maximum dose of extended-release oxycodone in opioid-tolerant pediatric patients; however, careful titration is required until tolerance develops to some of the side effects (i.e., drowsiness and respiratory depression). Individualize dosage carefully.
Extended-release tablets in Children younger than 11 years, immediate-release dosage forms, and extended-release capsules (Xtampza ER): Safety and efficacy have not been established.

Infants

Safety and efficacy have not been established.

Neonates

Safety and efficacy have not been established.

DOSING CONSIDERATIONS

Hepatic Impairment

Start initial therapy at one-third to one-half the normal dose and titrate dose carefully. Patients with hepatic impairment have higher plasma oxycodone and noroxycodone and lower oxymorphone concentrations than those with normal hepatic function.

Renal Impairment

Conservative initial dose and dose titration are required. Dosage should be modified depending on clinical response and degree of renal impairment. In patients with CrCl less than 60 mL/minute, the serum concentration of oxycodone is about 50% higher than in patients with normal renal function.

ADMINISTRATION

Oral Administration

Oxycodone should be titrated from the initial recommended dosage to the dose required to relieve the patient’s pain and minimize adverse reactions.
There is no maximum dose of oxycodone; however, careful titration is required to avoid adverse reactions (i.e., drowsiness and respiratory depression).

Oral Solid Formulations

Immediate-release tablets:
May be administered with food or milk to minimize GI irritation.
Oxecta and Oxaydo brand tablets: Swallow whole; do not crush or dissolve. Do not pre-soak, lick, or otherwise wet tablet prior to dose administration. Administer 1 tablet at a time; allow patient to swallow each tablet separately with sufficient liquid to ensure prompt and complete transit through the esophagus. Do not use this brand for administration via nasogastric, gastric, or other feeding tubes as it may cause obstruction of feeding tubes.

Extended-release tablets (e.g., OxyContin):
Administer whole; do not crush, chew, cut, dissolve, or break in half. Taking chewed, broken, cut, dissolved, or crushed extended-release tablets could lead to the rapid release and absorption of a potentially fatal dose of oxycodone.
OxyContin brand tablets: Do not pre-soak, lick, or otherwise wet tablet prior to dose administration. Administer 1 tablet at a time; allow patient to swallow each tablet separately with sufficient liquid to ensure prompt and complete transit through the esophagus.
May be administered with or without food.
Take with a full glass of water to ensure complete swallowing.
In general, administer one-half of the patient’s total daily dose every 12 hours. If asymmetric dosing is necessary, instruct patient to take the higher dose in the morning.
Extended-release 60 mg and 80 mg tablets are for use ONLY in opioid-tolerant patients.
Monitor patients closely for respiratory depression, particularly within the first 24 to 72 hours after initiation or dose escalation.

Extended-release capsules (Xtampza ER):
Always take with food and with approximately the same amount of food in order to ensure consistent plasma concentrations.
The capsule contents may be taken by sprinkling the contents onto soft foods (e.g., applesauce, pudding, yogurt, ice cream, or jam) or into a cup and then giving directly into the mouth. Swallow immediately and rinse mouth to ensure all capsule contents have been swallowed. Discard capsule shells following administration.
The capsule contents may be given through a nasogastric or gastrostomy tube. Flush the tube with water. Open a capsule and pour the contents directly into the tube. Do not pre-mix capsule contents with the liquid that will be used to flush the tube. Draw up 15 mL of water into a syringe, insert the syringe into the tube, and flush the contents through the tube. Repeat flushing twice using 10 mL of water with each flush. Milk or liquid nutritional supplement may be used as an alternative to water when flushing capsule contents through the tube.
Extended-release 36 mg capsules are for use ONLY in opioid-tolerant patients.
Monitor patients closely for respiratory depression, particularly within the first 24 to 72 hours after initiation or dose escalation.

Oral Liquid Formulations

Oral concentrate solution:
Always use an enclosed oral syringe when administering the highly concentrated solution (20 mg/mL); care should be taken in dispensing and administering this medication.
For ease of administration, Oxyfast concentrated 20 mg/mL solution may be added to 30 mL of a liquid or semi-solid food. If the medication is placed in liquid or food, the patient needs to immediately consume; do not store diluted oxycodone for future use.

STORAGE

Dazidox :
– Protect from moisture
– Store at controlled room temperature (between 68 and 77 degrees F)
Endocodone :
– Protect from moisture
– Store at controlled room temperature (between 68 and 77 degrees F)
ETH-Oxydose:
– Protect from light
– Protect from moisture
– Store at 77 degrees F; excursions permitted to 59-86 degrees F
Oxaydo:
– Protect from moisture
– Store at controlled room temperature (between 68 and 77 degrees F)
OXECTA:
– Protect from moisture
– Store at 77 degrees F; excursions permitted to 59-86 degrees F
OxyContin:
– Store at 77 degrees F; excursions permitted to 59-86 degrees F
Oxydose :
– Protect from light
– Protect from moisture
– Store at 77 degrees F; excursions permitted to 59-86 degrees F
OxyFast:
– Protect from light
– Protect from moisture
– Store at 77 degrees F; excursions permitted to 59-86 degrees F
OxyIR:
– Protect from light
– Protect from moisture
– Store at 77 degrees F; excursions permitted to 59-86 degrees F
Percolone:
– Protect from moisture
– Store at controlled room temperature (between 68 and 77 degrees F)
Roxicodone:
– Protect from light
– Protect from moisture
– Store at 77 degrees F; excursions permitted to 59-86 degrees F
ROXYBOND:
– Protect from moisture
– Store at controlled room temperature (between 68 and 77 degrees F)
XTAMPZA :
– Store at 77 degrees F; excursions permitted to 59-86 degrees F

Additional information

Tablets

25 tablets, 50 tablets, 100 tablets

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.